IBRX - יחס חוב להיוון בספרים ImmunityBio, Inc.

The transition to the commercial stage allows ImmunityBio, Inc. (IBRX) to rapidly expand its consumer reach due to the shortage of modern treatment methods. This price chart confirms the momentum of the biotech developer, which utilizes a unique NK-cell system to create Anktiva, a treatment for bladder tumors. The current indicator stands at 0.00, while the company generates revenue through settlements with insurance organizations and medical centers implementing this immunotherapy.

To filter out high-risk assets, investors utilize financial leverage analysis to assess the stability of an issuer's capital structure. This indicator measures the proportion of liabilities relative to equity, which allows for a comparison of debt levels against book capital to determine the extent to which the large-scale immunotherapy developments of ImmunityBio, Inc. (IBRX) conducted in collaboration with oncology centers are funded by borrowed funds or internal reserves.